Scroll

galantamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1272	357-70-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: galantamine galantamin galantamina lycoremin lycoremine galanthamine (-)-Galantamine (-)-Galanthamine galantamine hydrobromide galanthamine hydrobromide	A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. Molecular weight: 287.36 Formula: C17H21NO3 CLOGP: 1.02 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 41.93 ALOGS: -2.23 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

galantamine
galantamin
galantamina
lycoremin
lycoremine
galanthamine
(-)-Galantamine
(-)-Galanthamine
galantamine hydrobromide
galanthamine hydrobromide

A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.

Molecular weight: 287.36
Formula: C17H21NO3
CLOGP: 1.02
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 41.93
ALOGS: -2.23
ROTB: 1

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
16	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.45 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	2.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.83 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 28, 2001	FDA	JANSSEN PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Orthostatic hypotension	932.25	38.03	281	6376	29200	50569267
Sedation complication	929.48	38.03	218	6439	8548	50589919
Creatinine renal clearance decreased	913.54	38.03	228	6429	11653	50586814
Sedation	874.90	38.03	270	6387	30340	50568127
Cognitive disorder	836.51	38.03	285	6372	43838	50554629
Blood calcium decreased	779.09	38.03	226	6431	20480	50577987
Balance disorder	705.92	38.03	285	6372	70305	50528162
Depressed level of consciousness	628.65	38.03	241	6416	51712	50546755
Mobility decreased	481.31	38.03	226	6431	79722	50518745
Fall	456.55	38.03	364	6293	334568	50263899
Constipation	442.28	38.03	284	6373	185424	50413043
Hypotension	403.88	38.03	294	6363	235175	50363292
Toxicity to various agents	292.23	38.03	233	6424	212266	50386201
Pain	96.60	38.03	225	6432	578678	50019789
Drug ineffective	77.18	38.03	9	6648	819324	49779143
Product dispensing error	55.85	38.03	26	6631	8865	50589602
Pleurothotonus	52.29	38.03	15	6642	1286	50597181
Fatigue	49.36	38.03	16	6641	707585	49890882
Marasmus	46.79	38.03	11	6646	429	50598038

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Fall	62.14	22.60	82	2872	177096	29394477
Dysphagia	37.37	22.60	36	2918	54890	29516683
Post-traumatic stress disorder	35.58	22.60	11	2943	1611	29569962
Compartment syndrome	34.97	22.60	12	2942	2440	29569133
Fracture	33.81	22.60	15	2939	6038	29565535
Agitation	31.86	22.60	32	2922	51272	29520301
Hallucination	27.96	22.60	28	2926	44684	29526889
Increased bronchial secretion	27.56	22.60	9	2945	1572	29570001
Aggression	25.49	22.60	24	2930	35517	29536056
Miosis	24.07	22.60	13	2941	7996	29563577
Coombs negative haemolytic anaemia	23.91	22.60	5	2949	150	29571423
Loss of consciousness	23.86	22.60	33	2921	74023	29497550
Bradycardia	23.82	22.60	31	2923	65598	29505975
Hallucination, visual	23.41	22.60	16	2938	14999	29556574
Cholinergic syndrome	22.96	22.60	6	2948	480	29571093
Pneumonia aspiration	22.95	22.60	23	2931	36714	29534859

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	984.79	28.87	238	8636	10116	64479742
Creatinine renal clearance decreased	925.77	28.87	242	8632	14179	64475679
Orthostatic hypotension	844.83	28.87	295	8579	46443	64443415
Sedation	839.85	28.87	285	8589	41177	64448681
Cognitive disorder	830.85	28.87	304	8570	54783	64435075
Blood calcium decreased	780.30	28.87	240	8634	25314	64464544
Balance disorder	690.21	28.87	299	8575	83627	64406231
Depressed level of consciousness	604.19	28.87	270	8604	81166	64408692
Mobility decreased	503.66	28.87	242	8632	85598	64404260
Fall	501.63	28.87	430	8444	416396	64073462
Constipation	409.02	28.87	299	8575	229038	64260820
Hypotension	326.53	28.87	326	8548	380648	64109210
Toxicity to various agents	226.15	28.87	263	8611	363250	64126608
Pain	119.07	28.87	245	8629	553266	63936592
Drug ineffective	59.30	28.87	21	8853	840226	63649632
Marasmus	48.10	28.87	13	8861	855	64489003
Pleurothotonus	43.20	28.87	15	8859	2287	64487571
Bradycardia	33.39	28.87	59	8815	118160	64371698
Poriomania	31.70	28.87	7	8867	196	64489662
Agitation	31.53	28.87	49	8825	88318	64401540
Fracture	29.92	28.87	23	8851	18732	64471126
Loss of consciousness	29.66	28.87	64	8810	148301	64341557
Fatigue	29.42	28.87	36	8838	748694	63741164

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06DA04	NERVOUS SYSTEM PSYCHOANALEPTICS ANTI-DEMENTIA DRUGS Anticholinesterases
FDA MoA	N0000000177	Cholinesterase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D002800	Cholinesterase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018697	Nootropic Agents
MeSH PA	D010277	Parasympathomimetics
MeSH PA	D018373	Peripheral Nervous System Agents
FDA EPC	N0000175723	Cholinesterase Inhibitor
CHEBI has role	CHEBI:37733	EC 3.1.1.8 inhibitor
CHEBI has role	CHEBI:38323	cholinergic drugs
CHEBI has role	CHEBI:38462	acetylcholinesterase inhibitors
CHEBI has role	CHEBI:74530	curare poisoning antidote
CHEBI has role	CHEBI:76924	plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Alzheimer's disease	indication	26929004	DOID:10652
Diffuse Lewy body disease	off-label use	80098002
Moderate to Severe Alzheimer's Type Dementia	off-label use
Peptic ulcer	contraindication	13200003	DOID:750
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Gastrointestinal ulcer	contraindication	40845000
Bradycardia	contraindication	48867003
Duodenal ulcer disease	contraindication	51868009	DOID:1724
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Epilepsy	contraindication	84757009	DOID:1826
Kidney disease	contraindication	90708001	DOID:557
Asthma	contraindication	195967001	DOID:2841
Atrioventricular block	contraindication	233917008	DOID:0050820
Disease of liver	contraindication	235856003	DOID:409
Bladder outflow obstruction	contraindication	236645006
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.14	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN	INHIBITOR	Ki	7.21	CHEMBL	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	6.72	CHEMBL
Acetylcholinesterase	Enzyme		ACES_TORCA		IC50	6.44	CHEMBL
Acetylcholinesterase	Enzyme		ACES_MOUSE		IC50	5.60	CHEMBL
Butyrylcholinesterase; Protein Bche	Enzyme		Q9JKC1_RAT		IC50	5.23	CHEMBL
Acetylcholinesterase	Enzyme		ACES_RAT		IC50	6.27	CHEMBL
Acetylcholinesterase	Enzyme		ACES_ELEEL		Ki	6.37	CHEMBL
Acetylcholinesterase	Enzyme		ACES_BOVIN		IC50	5.06	CHEMBL
Butyrylcholinesterase	Enzyme		Q9N1N9_HORSE		Ki	5.10	CHEMBL
Cholinesterase	Enzyme		CHLE_HORSE		Ki	5.03	CHEMBL

External reference:

ID	Source
4021250	VUID
N0000148691	NUI
D02173	KEGG_DRUG
1953-04-4	SECONDARY_CAS_RN
4021250	VANDF
4021251	VANDF
C0016967	UMLSCUI
CHEBI:42944	CHEBI
GNT	PDB_CHEM_ID
CHEMBL659	ChEMBL_ID
DB00674	DRUGBANK_ID
CHEMBL1555	ChEMBL_ID
D005702	MESH_DESCRIPTOR_UI
9651	PUBCHEM_CID
6693	IUPHAR_LIGAND_ID
1392	INN_ID
0D3Q044KCA	UNII
4637	RXNORM
147848	MMSL
15913	MMSL
d04750	MMSL
007026	NDDF
007027	NDDF
129482002	SNOMEDCT_US
323377002	SNOMEDCT_US
395727007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Galantamine Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0137	SOLUTION	4 mg	ORAL	ANDA	24 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3496	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3496	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3497	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3497	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3498	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3498	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
Galantamine	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7104	TABLET, FILM COATED	4 mg	ORAL	ANDA	26 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0881	TABLET, FILM COATED	4 mg	ORAL	NDA	27 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0882	TABLET, FILM COATED	8 mg	ORAL	NDA	27 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0883	TABLET, FILM COATED	12 mg	ORAL	NDA	27 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0891	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	NDA	27 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0892	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	NDA	27 sections
galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	10147-0893	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	NDA	27 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-184	TABLET, FILM COATED	8 mg	ORAL	NDA	20 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-591	TABLET, FILM COATED	12 mg	ORAL	NDA	20 sections
Galantamine hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	43353-984	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	20 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-835	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-836	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	ANDA	25 sections
Galantamine Hydrobromide	Human Prescription Drug Label	1	47335-837	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	ANDA	25 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-387	CAPSULE, EXTENDED RELEASE	8 mg	ORAL	NDA	26 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-388	CAPSULE, EXTENDED RELEASE	16 mg	ORAL	NDA	26 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-389	CAPSULE, EXTENDED RELEASE	24 mg	ORAL	NDA	26 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-396	TABLET, FILM COATED	4 mg	ORAL	NDA	26 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-397	TABLET, FILM COATED	8 mg	ORAL	NDA	26 sections
RAZADYNE	HUMAN PRESCRIPTION DRUG LABEL	1	50458-398	TABLET, FILM COATED	12 mg	ORAL	NDA	26 sections
Galantamine Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	51990-111	TABLET, FILM COATED	4 mg	ORAL	NDA	26 sections
Galantamine Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	51990-112	TABLET, FILM COATED	8 mg	ORAL	NDA	26 sections
Galantamine Hydrobromide	HUMAN PRESCRIPTION DRUG LABEL	1	51990-113	TABLET, FILM COATED	12 mg	ORAL	NDA	26 sections
Galantamine	Human Prescription Drug Label	1	57237-049	TABLET, FILM COATED	4 mg	ORAL	ANDA	25 sections